Skip to content Skip to footer
Subscribe Now
Viewpoints_Andrew Menzies-Gow
VIEWPOINTS

AstraZeneca at ATS’24: Andrew Menzies-Gow from AstraZeneca in a Stimulating Conversation with PharmaShots

Shots: AstraZeneca presented 59 abstracts, including 12 late-breaking posters at the American Thoracic Society, focussing on the unmet needs in COPD, EGPA, and other chronic respiratory diseases Today, at PharmaShots, we have Andrew Menzies-Gow, sharing insights from the MANDARA study that evaluated Fasenra (benralizumab) for EGPA, a rare debilitating condition Andrew stresses reducing the use…
July 3, 2024

Read more

VIEWPOINTS_Donna Carstens_2024
VIEWPOINTS

SEA Management: Donna Carstens from AstraZeneca in a Riveting Conversation with PharmaShots

Shots: Recently AstraZeneca’s FASENRA (benralizumab) received approval from the US FDA as an add-on maintenance treatment for patients (≥ 6 yrs.) with severe asthma and with an eosinophilic phenotype Today, at PharmaShots we have with us Donna Carstens, Senior Medical Director Respiratory, Fasenra at AstraZeneca Donna shares insights from the TATE study an open-label, multinational,…
June 3, 2024

Read more

VIEWPOINTS_David Jackson_2024
VIEWPOINTS

SEA Management with Fasenra: David Jackson & Fasenra Team (AZ) Share Insights from the SHAMAL P-IV Study

Shots: David Jackson and AstraZeneca’s Fasenra Team, in an engaging conversation with PharmaShots highlight the key findings from the SHAMAL P-IV study SHAMAL is the first-ever prospective study that investigated the potential of targeted biologic treatment to enable a significant step down of inhaled corticosteroid (ICS) therapy in severe asthma patients SHAMAL showcased that ICS…
March 20, 2024

Read more

VIEWPOINTS_Andrew Menzies-Gow1_2024
VIEWPOINTS

AstraZeneca at ACR 2023: Andrew Menzies-Gow Highlights Data from the MANDARA Study

Shots: Andrew Menzies-Gow, in a stimulating conversation with PharmaShots, shares the insights from the Phase III MANDARA study that evaluates Fasenra (benralizumab) vs. mepolizumab for patients with relapsing or refractory EGPA Five out of the 18 abstracts presented by AstraZeneca at ACR were from the MANDARA study. Apart from the positive endpoints of the MANDARA…
February 6, 2024

Read more

VIEWPOINTS_Andrew Menzies-Gow2_2024
VIEWPOINTS

Andrew Menzies-Gow Shares Insights from Phase III MANDARA Trial of Fasenra for EGPA Patients

Shots While sharing the details on Fasenra, Andrew highlights the unmet medical need in the healthcare sector as there’s only one approved treatment for EGPA With mepolizumab as the comparator drug for the trial, Andrew shares the positive results in achieving remission rates. Andrew sheds light on the unique mechanism of benralizumab that directly targets…
December 4, 2023

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]